Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANENCA trial for prevention of complications after high-risk pancreatoduodenectomy
2024-519667-18-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2025
- Modality
- Small Molecules, Peptides
- Countries
- 7
01
Overview
Phase 4, randomised, open-label trial of hydrocortisone and octreotide in pancreatic cancer (PC) and intraductal papillary mucinous neoplasm (IPMN) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Rate of major complications. Planned start Aug 2025; status: authorised.
02
Drugs
hydrocortisoneoctreotide
03
Conditions
pancreatic cancer (PC)intraductal papillary mucinous neoplasm (IPMN)
Beyond the preview
Go deeper on 2024-519667-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519667-18-00.